{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:02:57Z","timestamp":1777982577449,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["T\u00dcB\u0130TAK B\u0130DEB 2210"],"award-info":[{"award-number":["T\u00dcB\u0130TAK B\u0130DEB 2210"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018847","name":"Sel\u00e7uk University Research Foundation","doi-asserted-by":"publisher","award":["24202058"],"award-info":[{"award-number":["24202058"]}],"id":[{"id":"10.13039\/501100018847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10637-026-01601-7","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:53:52Z","timestamp":1769417632000},"page":"9-22","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, synthesis, anticancer activity, bioimaging, and molecular docking of novel fluorescent isatin derivatives"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5457-4294","authenticated-orcid":false,"given":"Merve","family":"\u0130nel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1219-5514","authenticated-orcid":false,"given":"Ayse","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-160X","authenticated-orcid":false,"given":"Mustafa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2654-7621","authenticated-orcid":false,"given":"Bahadir","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"1601_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer 149:778\u2013789. https:\/\/doi.org\/10.1002\/ijc.33588","journal-title":"Int J Cancer"},{"key":"1601_CR2","unstructured":"WHO (2022) Global cancer observatory 2022. In: https:\/\/gco.iarc.fr\/en. Accessed 22 Apr 2025"},{"key":"1601_CR3","unstructured":"Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 TC (2020) 2020 Y\u0131l\u0131 T\u00fcrkiye Kanser \u0130statistikleri. In: https:\/\/hsgm.saglik.gov.tr\/depo\/birimler\/kanser-db\/Dokumanlar\/Istatistikler\/Turkiye_Kanser_Istatistikleri_2020.pdf.\u00a0Accessed 22 Apr 2025"},{"key":"1601_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00342-0","volume":"5","author":"X Fu","year":"2020","unstructured":"Fu X, Shi Y, Qi T et al (2020) Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting. Signal Transduct Target Ther 5:262. https:\/\/doi.org\/10.1038\/s41392-020-00342-0","journal-title":"Signal Transduct Target Ther"},{"key":"1601_CR5","doi-asserted-by":"publisher","unstructured":"Orbay S, Sanyal R, Sanyal A (2023) Porous microgels for delivery of curcumin: microfluidics-based fabrication and cytotoxicity evaluation. Micromachines (Basel) 14. https:\/\/doi.org\/10.3390\/mi14101969","DOI":"10.3390\/mi14101969"},{"key":"1601_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1876","volume":"33","author":"HS Orer","year":"2022","unstructured":"Orer HS, Nomak G, Oksuzoglu B et al (2022) 1200TiP Phase Ia\/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC). Ann Oncol 33:S1097. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1876","journal-title":"Ann Oncol"},{"key":"1601_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.967720","volume":"10","author":"T Bagci-Onder","year":"2022","unstructured":"Bagci-Onder T, Kutuk O, Chonghaile TN, Knippschild U (2022) Editorial: cell death and targeted cancer therapies. Front Cell Dev Biol 10:967720. https:\/\/doi.org\/10.3389\/fcell.2022.967720","journal-title":"Front Cell Dev Biol"},{"key":"1601_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.canlet.2008.08.031","volume":"274","author":"S Oh","year":"2009","unstructured":"Oh S, Kim BJ, Singh NP et al (2009) Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett 274:33\u201339. https:\/\/doi.org\/10.1016\/j.canlet.2008.08.031","journal-title":"Cancer Lett"},{"key":"1601_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201900367","volume":"353","author":"Z Ding","year":"2020","unstructured":"Ding Z, Zhou M, Zeng C (2020) Recent advances in isatin hybrids as potential anticancer agents. Arch Pharm Weinheim 353:1900367. https:\/\/doi.org\/10.1002\/ardp.201900367","journal-title":"Arch Pharm Weinheim"},{"key":"1601_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1021\/acsmedchemlett.8b00596","volume":"10","author":"R Meleddu","year":"2019","unstructured":"Meleddu R, Petrikaite V, Distinto S et al (2019) Investigating the anticancer activity of isatin\/dihydropyrazole hybrids. ACS Med Chem Lett 10:571\u2013576. https:\/\/doi.org\/10.1021\/acsmedchemlett.8b00596","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"1601_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2174\/1871520610909040397","volume":"9","author":"KL Vine","year":"2009","unstructured":"Vine KL, Matesic L, Locke JM et al (2009) Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000-2008. Anticancer Agents Med Chem 9(4):397\u2013414. https:\/\/doi.org\/10.2174\/1871520610909040397","journal-title":"Anticancer Agents Med Chem"},{"key":"1601_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/biof.1408","volume":"44","author":"A Medvedev","year":"2018","unstructured":"Medvedev A, Buneeva O, Gnedenko O et al (2018) Isatin, an endogenous nonpeptide biofactor: a review of its molecular targets, mechanisms of actions, and their biomedical implications. BioFactors 44:95\u2013108. https:\/\/doi.org\/10.1002\/biof.1408","journal-title":"BioFactors"},{"issue":"4","key":"1601_CR13","first-page":"829","volume":"4","author":"CN Nalini","year":"2011","unstructured":"Nalini CN, Deepthi S, Baid C (2011) Toxicity risk assesment of isatins. Rasayan J Chem 4(4):829\u2013833","journal-title":"Rasayan J Chem"},{"issue":"5","key":"1601_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2174\/157340610793358909","volume":"6","author":"PK Ramshid","year":"2010","unstructured":"Ramshid PK, Jagadeeshan S, Krishnan A et al (2010) Synthesis and in vitro evaluation of some isatin-thiazolidinone hybrid analogues as anti-proliferative agents. Med Chem 6(5):306\u2013312. https:\/\/doi.org\/10.2174\/157340610793358909","journal-title":"Med Chem"},{"key":"1601_CR15","doi-asserted-by":"publisher","first-page":"32188","DOI":"10.1039\/D5RA05002B","volume":"15","author":"MA Alshams","year":"2025","unstructured":"Alshams MA, Nafie MS, Ashour HF, Yassen ASA (2025) A comprehensive review and recent advances on isatin-based compounds as a versatile framework for anticancer therapeutics (2020\u20132025). RSC Adv 15:32188\u201332231. https:\/\/doi.org\/10.1039\/D5RA05002B","journal-title":"RSC Adv"},{"key":"1601_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2023.117586","volume":"98","author":"A Oguz","year":"2024","unstructured":"Oguz A, Saglik BN, Oguz M et al (2024) Novel mitochondrial and DNA damaging fluorescent Calix[4]arenes bearing isatin groups as aromatase inhibitors: design, synthesis and anticancer activity. Bioorg Med Chem 98:117586. https:\/\/doi.org\/10.1016\/j.bmc.2023.117586","journal-title":"Bioorg Med Chem"},{"key":"1601_CR17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1021\/jm501562a","volume":"58","author":"GJ Roth","year":"2015","unstructured":"Roth GJ, Binder R, Colbatzky F et al (2015) Nintedanib: from discovery to the clinic. J Med Chem 58:1053\u20131063. https:\/\/doi.org\/10.1021\/jm501562a","journal-title":"J Med Chem"},{"issue":"1","key":"1601_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/00304948.2024.2365517","volume":"57","author":"HAM Rasheed","year":"2024","unstructured":"Rasheed HAM, Al-Majidi SMH (2024) Synthesis of novel 1,2,4-triazole derivatives of N-Benzyl-5-nitroisatin: anticancer activity, anti-oxidant activity, and molecular design. Org Prep Proced Int 57(1):39. https:\/\/doi.org\/10.1080\/00304948.2024.2365517","journal-title":"Org Prep Proced Int"},{"key":"1601_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ajoc.201300153","volume":"2","author":"A Kundu","year":"2013","unstructured":"Kundu A, Pathak S, Pramanik A (2013) Synthesis and fluorescence properties of isatin-based spiro compounds: switch off chemosensing of copper(II) ions. Asian J Org Chem 2:869\u2013876. https:\/\/doi.org\/10.1002\/ajoc.201300153","journal-title":"Asian J Org Chem"},{"key":"1601_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.dyepig.2021.109559","volume":"194","author":"Y-F Wei","year":"2021","unstructured":"Wei Y-F, Zhang X-Q, Sun R et al (2021) Fluorescent probes based 1,8-naphthalimide-nitrogen heterocyclic for monitoring the fluctuation of mitochondrial viscosity. Dyes Pigments 194:109559. https:\/\/doi.org\/10.1016\/j.dyepig.2021.109559","journal-title":"Dyes Pigments"},{"key":"1601_CR21","doi-asserted-by":"publisher","first-page":"47342","DOI":"10.1021\/acsomega.4c09069","volume":"9","author":"MD Yilmaz","year":"2024","unstructured":"Yilmaz MD, Altves S, Erbas-Cakmak S (2024) Naturally occurring flavonol, quercetagetin 5,6,7,3\u2032,4\u2032-pentamethyl ether (Marionol), as a nontoxic plant-based fluorescent probe for rapid, sensitive, and selective detection of Cu2+ in water. ACS Omega 9:47342\u201347349. https:\/\/doi.org\/10.1021\/acsomega.4c09069","journal-title":"ACS Omega"},{"key":"1601_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202402053","volume":"9","author":"LEL Mchichi","year":"2024","unstructured":"Mchichi LEL, Alaqarbeh M, Lakhl\u0131f\u0131 T, Bouachr\u0131ne M (2024) Discovery of a new isatin scaffold for BCR-ABL tyrosine kinase inhibitors using a comprehensive computational approach. ChemistrySelect 9:e202402053. https:\/\/doi.org\/10.1002\/slct.202402053","journal-title":"ChemistrySelect"},{"key":"1601_CR23","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.3390\/app11093746","volume":"11","author":"HSA Al-Salem","year":"2021","unstructured":"Al-Salem HSA, Arifuzzaman M, Issa IS, Rahman AFMM (2021) Isatin-hydrazones with multiple receptor tyrosine kinases (RTKs) inhibitory activity and in-silico binding mechanism. Appl Sci 11:3746. https:\/\/doi.org\/10.3390\/app11093746","journal-title":"Appl Sci"},{"key":"1601_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21608\/ejchem.2021.72747.3607","volume":"65","author":"NW Ibrahim","year":"2022","unstructured":"Ibrahim NW, Mahdi M, Raauf AMR (2022) Design, molecular docking, synthesis and evaluation of new isatin derivatives bearing pyridine moiety as potential tyrosine kinase inhibitors. Egypt J Chem 65:9\u201318. https:\/\/doi.org\/10.21608\/ejchem.2021.72747.3607","journal-title":"Egypt J Chem"},{"key":"1601_CR25","doi-asserted-by":"publisher","first-page":"W32","DOI":"10.1093\/nar\/gku293","volume":"42","author":"D Gfeller","year":"2014","unstructured":"Gfeller D, Grosdidier A, Wirth M et al (2014) SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res 42:W32\u2013W38. https:\/\/doi.org\/10.1093\/nar\/gku293","journal-title":"Nucleic Acids Res"},{"key":"1601_CR26","doi-asserted-by":"publisher","unstructured":"(2010) VEGFR2 kinase domain bound to sunitinib (PDB ID: 4AGD). https:\/\/doi.org\/10.2210\/pdb4AGD\/pdb","DOI":"10.2210\/pdb4AGD\/pdb"},{"key":"1601_CR27","doi-asserted-by":"publisher","unstructured":"(2009) KIT kinase domain bound to sunitinib (PDB ID: 3G0E). https:\/\/doi.org\/10.2210\/pdb3G0E\/pdb","DOI":"10.2210\/pdb3G0E\/pdb"},{"key":"1601_CR28","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1073\/pnas.0812413106","volume":"106","author":"KS Gajiwala","year":"2009","unstructured":"Gajiwala KS, Wu JC, Christensen J et al (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 106:1542\u20131547. https:\/\/doi.org\/10.1073\/pnas.0812413106","journal-title":"Proc Natl Acad Sci USA"},{"key":"1601_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4161\/cbt.10.1.12162","volume":"10","author":"K Laderoute","year":"2010","unstructured":"Laderoute K, Calaoagan JM, Madrid PB et al (2010) SU11248 (sunitinib) directly inhibits the activity of mammalian 5\u2019-AMP-activated protein kinase (AMPK). Cancer Biol Ther 10:68\u201376. https:\/\/doi.org\/10.4161\/cbt.10.1.12162","journal-title":"Cancer Biol Ther"},{"key":"1601_CR30","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt J, Santos-Martins D, Tillack AF, Forli S (2021) AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings. J Chem Inf Model 61:3891\u20133898. https:\/\/doi.org\/10.1021\/acs.jcim.1c00203","journal-title":"J Chem Inf Model"},{"key":"1601_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334","journal-title":"J Comput Chem"},{"key":"1601_CR32","doi-asserted-by":"publisher","unstructured":"Muhammed TM, Ak\u0131-yalc\u0131n E (2021) Pharmacophore modeling in drug discovery: methodology and current status. J Turk Chem Soc Sect A Chem 8:749\u2013762.\u00a0https:\/\/doi.org\/10.18596\/jotcsa.927426","DOI":"10.18596\/jotcsa.927426"},{"key":"1601_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1006\/excr.2000.4838","volume":"256","author":"SH Kaufmann","year":"2000","unstructured":"Kaufmann SH, Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42\u201349. https:\/\/doi.org\/10.1006\/excr.2000.4838","journal-title":"Exp Cell Res"},{"key":"1601_CR34","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3892\/or.2014.3426","volume":"32","author":"Z Ma","year":"2014","unstructured":"Ma Z, Hou L, Jiang Y et al (2014) The endogenous oxindole isatin induces apoptosis of MCF-7 breast cancer cells through a mitochondrial pathway. Oncol Rep 32:2111\u20132117. https:\/\/doi.org\/10.3892\/or.2014.3426","journal-title":"Oncol Rep"},{"key":"1601_CR35","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:1060\u20131072. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042","journal-title":"Cell"},{"key":"1601_CR36","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/ijc.24064","volume":"124","author":"S Fulda","year":"2009","unstructured":"Fulda S (2009) Tumor resistance to apoptosis. Int J Cancer 124:511\u2013515. https:\/\/doi.org\/10.1002\/ijc.24064","journal-title":"Int J Cancer"},{"key":"1601_CR37","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"1601_CR38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrc3365","volume":"12","author":"DC Wallace","year":"2012","unstructured":"Wallace DC (2012) Mitochondria and cancer. Nat Rev Cancer 12:685\u2013698. https:\/\/doi.org\/10.1038\/nrc3365","journal-title":"Nat Rev Cancer"},{"key":"1601_CR39","doi-asserted-by":"publisher","first-page":"9653","DOI":"10.2174\/0109298673368188250613112621","volume":"32","author":"M \u0130nel","year":"2025","unstructured":"\u0130nel M, Yildirim A, Ozturk B, Yilmaz M (2025) Recent advances in the application of mitochondria-targeted fluorescent probes. Curr Med Chem 32:9653\u20139678. https:\/\/doi.org\/10.2174\/0109298673368188250613112621","journal-title":"Curr Med Chem"},{"key":"1601_CR40","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1021\/ci060117s","volume":"46","author":"GM Maggiora","year":"2006","unstructured":"Maggiora GM (2006) On outliers and activity cliffsWhy QSAR often disappoints. J Chem Inf Model 46:1535. https:\/\/doi.org\/10.1021\/ci060117s","journal-title":"J Chem Inf Model"},{"issue":"7","key":"1601_CR41","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQM Chow","year":"2007","unstructured":"Chow LQM, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25(7):884\u2013896. https:\/\/doi.org\/10.1200\/JCO.2006.06.3602","journal-title":"J Clin Oncol"},{"issue":"Pt 5","key":"1601_CR42","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1107\/S1399004714002351","volume":"70","author":"M Mali\u0144ska","year":"2014","unstructured":"Mali\u0144ska M, Jarzembska KN, G\u00f3ral A et al (2014) Sunitinib: from charge-density studies to interaction with proteins. Acta Crystallogr D Biol Crystallogr 70(Pt 5):1257\u20131270. https:\/\/doi.org\/10.1107\/S1399004714002351","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"1601_CR43","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/cbdd.13493","volume":"93","author":"Y Wang","year":"2019","unstructured":"Wang Y, Peng C, Wang G et al (2019) Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation. Chem Biol Drug Des 93:934\u2013948. https:\/\/doi.org\/10.1111\/cbdd.13493","journal-title":"Chem Biol Drug Des"},{"key":"1601_CR44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ejmech.2012.10.020","volume":"58","author":"J Caballero","year":"2012","unstructured":"Caballero J, Mu\u00f1oz C, Alzate-Morales JH et al (2012) Synthesis, in silico, in vitro, and in vivo investigation of 5-[11C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR2. Eur J Med Chem 58:272\u2013280. https:\/\/doi.org\/10.1016\/j.ejmech.2012.10.020","journal-title":"Eur J Med Chem"},{"issue":"1","key":"1601_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.31248\/JDPS2017.007","volume":"1","author":"KK Igwe","year":"2017","unstructured":"Igwe KK, Otuokere IE, Ikpeazu OV (2017) Probing the binding sites, global energy and molecular interactions between ponatinib, cabozantinib and sunitinib anticancer drugs with vascular endothelial growth factor. J Drugs Pharm Sci 1(1):9\u201315. https:\/\/doi.org\/10.31248\/JDPS2017.007","journal-title":"J Drugs Pharm Sci"},{"key":"1601_CR46","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1158\/1078-0432.CCR-13-1323","volume":"19","author":"SD Baker","year":"2013","unstructured":"Baker SD, Zimmerman EI, Wang Y-D et al (2013) Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD\u2013positive acute myeloid leukemia. Clin Cancer Res 19:5758\u20135768. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1323","journal-title":"Clin Cancer Res"},{"key":"1601_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11030-015-9635-x","volume":"20","author":"P Chaudhari","year":"2016","unstructured":"Chaudhari P, Bari S (2016) In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening. Mol Divers 20:41\u201353. https:\/\/doi.org\/10.1007\/s11030-015-9635-x","journal-title":"Mol Divers"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01601-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01601-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01601-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:53:37Z","timestamp":1777294417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01601-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1601"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01601-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8105007\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work does not involve the use of humans or animals. All cell lines were obtained from ATCC, and the authors comply with institutional guidelines for cell culture.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}